BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 8637027)

  • 1. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines.
    Kaufmann SH; Peereboom D; Buckwalter CA; Svingen PA; Grochow LB; Donehower RC; Rowinsky EK
    J Natl Cancer Inst; 1996 Jun; 88(11):734-41. PubMed ID: 8637027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines.
    Janss AJ; Cnaan A; Zhao H; Shpilsky A; Levow C; Sutton L; Phillips PC
    Anticancer Drugs; 1998 Aug; 9(7):641-52. PubMed ID: 9773809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.
    Jensen PB; Holm B; Sorensen M; Christensen IJ; Sehested M
    Br J Cancer; 1997; 75(6):869-77. PubMed ID: 9062409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal.
    Adjei AA; Budihardjo II; Rowinsky EK; Kottke TJ; Svingen PA; Buckwalter CA; Grochow LB; Donehower RC; Kaufmann SH
    Clin Cancer Res; 1997 May; 3(5):761-70. PubMed ID: 9815747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines.
    Viale M; Pastrone I; Pellecchia C; Vannozzi MO; Cafaggi S; Esposito M
    Anticancer Drugs; 1998 Jun; 9(5):457-63. PubMed ID: 9660544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.
    Chou TC; Motzer RJ; Tong Y; Bosl GJ
    J Natl Cancer Inst; 1994 Oct; 86(20):1517-24. PubMed ID: 7932806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro.
    Ma J; Maliepaard M; Nooter K; Boersma AW; Verweij J; Stoter G; Schellens JH
    Cancer Chemother Pharmacol; 1998; 41(4):307-16. PubMed ID: 9488600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells.
    Shingu T; Yamada K; Hara N; Moritake K; Osago H; Terashima M; Uemura T; Yamasaki T; Tsuchiya M
    Cancer Res; 2003 Jul; 63(14):4044-7. PubMed ID: 12874004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence.
    Rowinsky EK; Kaufmann SH; Baker SD; Grochow LB; Chen TL; Peereboom D; Bowling MK; Sartorius SE; Ettinger DS; Forastiere AA; Donehower RC
    J Clin Oncol; 1996 Dec; 14(12):3074-84. PubMed ID: 8955652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-neoplastic activity of topotecan versus cisplatin, etoposide and paclitaxel in four squamous cell cancer cell lines of the female genital tract using an ATP-Tumor Chemosensitivity Assay.
    Boabang P; Kurbacher CM; Kohlhagen H; Waida A; Amo-Takyi BK
    Anticancer Drugs; 2000 Nov; 11(10):843-8. PubMed ID: 11142692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens.
    Cheng MF; Chatterjee S; Berger NA
    Oncol Res; 1994; 6(6):269-79. PubMed ID: 7865902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
    Erlichman C; Boerner SA; Hallgren CG; Spieker R; Wang XY; James CD; Scheffer GL; Maliepaard M; Ross DD; Bible KC; Kaufmann SH
    Cancer Res; 2001 Jan; 61(2):739-48. PubMed ID: 11212277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of the minor groove-binder U73-975 or the intercalator mitoxantrone with antitumor alkylating agents in MCF-7 or MCF-7/CP cells.
    Ayash L; Korbut T; Herman TS; Teicher BA
    Cancer Lett; 1991 Dec; 61(1):7-14. PubMed ID: 1764699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.
    Schwartz GN; Teicher BA; Eder JP; Korbut T; Holden SA; Ara G; Herman TS
    Cancer Chemother Pharmacol; 1993; 32(6):455-62. PubMed ID: 8258194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.
    Hendricks CB; Rowinsky EK; Grochow LB; Donehower RC; Kaufmann SH
    Cancer Res; 1992 Apr; 52(8):2268-78. PubMed ID: 1348448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
    Kawano M; Mabuchi S; Kishimoto T; Hisamatsu T; Matsumoto Y; Sasano T; Takahashi R; Sawada K; Takahashi K; Takahashi T; Hamasaki T; Kimura T
    Int J Gynecol Cancer; 2014 Jun; 24(5):829-37. PubMed ID: 24844217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines.
    Taron M; Plasencia C; Abad A; Martin C; Guillot M
    Invest New Drugs; 2000 May; 18(2):139-47. PubMed ID: 10857993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
    Romanelli S; Perego P; Pratesi G; Carenini N; Tortoreto M; Zunino F
    Cancer Chemother Pharmacol; 1998; 41(5):385-90. PubMed ID: 9523734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The significance of the sequence of administration of topotecan and etoposide.
    Bonner JA; Kozelsky TF
    Cancer Chemother Pharmacol; 1996; 39(1-2):109-12. PubMed ID: 8995507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines.
    Adjei AA; Davis JN; Bruzek LM; Erlichman C; Kaufmann SH
    Clin Cancer Res; 2001 May; 7(5):1438-45. PubMed ID: 11350915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.